BrightGene Bio-Medical Technology Co., Ltd (stock code: 688166) is an innovative pharmaceutical enterprise participating in international competition. Relying on R&D drive, the company focuses on the first imitation, difficult imitation, characteristic APIs, complex preparations and original new drugs, continues to create high-tech barriers, gradually establishes a business system that integrates APIs and preparations, combines generic drugs with innovative drugs, and pays equal attention to the international market and domestic market, and is committed to meeting the unmet clinical needs of patients worldwide.

With the goal of "continuous innovation and health protection", BrightGene provides patients with products with outstanding value. Through years of accumulation, drug technology research and development platforms such as fermentation semi synthesis platform, multi chiral drug platform, non biological macromolecule platform, drug machinery combination platform and coupling drug platform have been formed, and the products cover fields such as antifungal, anti-virus, immunosuppression, anti-tumor, cardiovascular and cerebrovascular, respiration, iron supplements, veterinary drugs, excipients, etc. 

The company's drug production system has passed the official GMP certification of China, the United States, the European Union, Japan and South Korea, and its products cover China, the European Union, the United States, Japan and South Korea, as well as other "the Belt and Road" countries or regions. A number of pharmaceutical intermediates and API products independently developed and produced by the company have been registered with DMF in major international standard market countries such as the United States, Europe, Japan and South Korea and China, and have been cited by customers, establishing a product line with global competitive advantages. With strong R&D strength as the cornerstone of development, BrightGene has made rapid development relying on the cGMP production quality system that is in line with international standards, as well as its global registration and commercialization capabilities.

At the same time,BrightGene has been through the whole industrial chain from "starting materials → highly difficult intermediates → characteristic APIs → preparations", becoming a leading enterprise and international pioneer in the Chinese pharmaceutical industry.

BrightGene adheres to the principle of "people-oriented", provides broad development space for all kinds of talents ,provides patients with high-quality, effective, safe and reliable cost-effective drugs, and creates a warm and healthy social living environment. Combining high productivity and cost-effective resources, along with unmatched regulatory and technical know-how, BrightGene is uniquely positioned to compete in the global pharmaceutical industry, particularly the fast growing specialty pharmaceutical sector.